Core Insights - Turn Therapeutics has entered into a global supply, development, and license agreement with Medline, enhancing its capabilities in dermatology, wound care, and anti-infective therapies [1][2][3] Company Overview - Turn Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for dermatology, wound care, and infectious diseases, with three FDA clearances for its proprietary formulations [5] - The company is advancing late-stage clinical programs in eczema and onychomycosis and is also involved in global health initiatives for thermostable vaccine delivery [5] Partnership Details - The collaboration with Medline aims to leverage Turn's proprietary PermaFusion® delivery platform for product development, manufacturing, and commercialization [2][3] - Medline is recognized as the largest provider of medical-surgical products and supply chain solutions, operating in over 100 countries and employing more than 43,000 people [4] Strategic Implications - The partnership is viewed as a transformative milestone for Turn, allowing the company to focus on scientific innovation while utilizing Medline's extensive infrastructure to reach professional and consumer markets [3]